DDInter410 DDInter1376
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic ser
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Clomipramine {u} (Compound) resembles {v} (Compound) Adinazolam
Clomipramine {u} (Compound) resembles {v} (Compound) Thioridazine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Clomipramine {u} (Compound) binds {v} (Gene) CYP1A2
Clomipramine {u} (Compound) upregulates {v} (Gene) TGFBR2
Clomipramine {u} (Compound) palliates {v} (Disease) panic disorder
Clomipramine {u} (Compound) causes {v} (Side Effect) Uterine haemorrhage
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ammonium chloride
Clomipramine (Compound) resembles Adinazolam (Compound)
Clomipramine (Compound) resembles Thioridazine (Compound)
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Clomipramine (Compound) binds CYP1A2 (Gene)
Clomipramine (Compound) upregulates TGFBR2 (Gene)
Clomipramine (Compound) palliates panic disorder (Disease)
Clomipramine (Compound) causes Uterine haemorrhage (Side Effect)
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride